A Pilot Study of Perillyl Alcohol in Pancreatic Cancer

Jesus M. Matos, C. Schmidt, Thomas Howard, Oscar Cummings, Eric A. Wiebke, James A. Madura, Patrick Loehrer, P. L. Crowell

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Chemotherapy has been largely unsuccessful in pancreatic cancer. Measurement of cell-specific biological endpoints may clarify the evaluation of a newer generation of compounds. Perillyl alcohol has shown chemotherapeutic activity in preclinical systems through enhancing apoptosis. Aims: To pilot a new trial template for testing novel agents in pancreatic cancer and to assess the biological activity of perillyl alcohol in patients with resectable pancreatic cancer. Methods: Apoptosis was quantified with ApopTag in situ, Bak staining, and light microscopy. Tumor size, serum CA 19-9 level, and survival were also measured. Results: Eight patients enrolled. Toxicity was mild and perillyl alcohol was generally well tolerated. Tumor size and CA 19-9 level were unchanged with perillyl alcohol treatment. Survival time was longer in patients who received full perillyl alcohol treatment (288 ± 32 days) compared to those who did not (204 ± 96 days), but this result did not achieve statistical significance (P = 0.2). There was a trend toward greater apoptosis in patients receiving perillyl alcohol compared to fresh operative controls; there was also a suggestion of greater apoptosis in tumor compared to normal pancreatic tissue in the same patient. Conclusions: Incorporation of cell-specific biological endpoints is challenging but feasible and should be used in clinical studies of pancreatic cancer treatment. Our pilot study suggests that perillyl alcohol may indeed have effects on biological endpoints. This study will serve as a useful template for examining cell-specific biological endpoints in the testing of future agents that are thought to induce apoptosis in pancreatic cancer.

Original languageEnglish
Pages (from-to)194-199
Number of pages6
JournalJournal of Surgical Research
Volume147
Issue number2
DOIs
StatePublished - Jun 15 2008

Fingerprint

perilla alcohol
Pancreatic Neoplasms
Apoptosis
Neoplasms
Survival
Microscopy
Therapeutics

Keywords

  • apoptosis
  • Bak
  • pancreatic cancer
  • perillyl alcohol

ASJC Scopus subject areas

  • Surgery

Cite this

A Pilot Study of Perillyl Alcohol in Pancreatic Cancer. / Matos, Jesus M.; Schmidt, C.; Howard, Thomas; Cummings, Oscar; Wiebke, Eric A.; Madura, James A.; Loehrer, Patrick; Crowell, P. L.

In: Journal of Surgical Research, Vol. 147, No. 2, 15.06.2008, p. 194-199.

Research output: Contribution to journalArticle

Matos, Jesus M. ; Schmidt, C. ; Howard, Thomas ; Cummings, Oscar ; Wiebke, Eric A. ; Madura, James A. ; Loehrer, Patrick ; Crowell, P. L. / A Pilot Study of Perillyl Alcohol in Pancreatic Cancer. In: Journal of Surgical Research. 2008 ; Vol. 147, No. 2. pp. 194-199.
@article{6b36cda4f27c44c1a5b4298ccd8e51c8,
title = "A Pilot Study of Perillyl Alcohol in Pancreatic Cancer",
abstract = "Background: Chemotherapy has been largely unsuccessful in pancreatic cancer. Measurement of cell-specific biological endpoints may clarify the evaluation of a newer generation of compounds. Perillyl alcohol has shown chemotherapeutic activity in preclinical systems through enhancing apoptosis. Aims: To pilot a new trial template for testing novel agents in pancreatic cancer and to assess the biological activity of perillyl alcohol in patients with resectable pancreatic cancer. Methods: Apoptosis was quantified with ApopTag in situ, Bak staining, and light microscopy. Tumor size, serum CA 19-9 level, and survival were also measured. Results: Eight patients enrolled. Toxicity was mild and perillyl alcohol was generally well tolerated. Tumor size and CA 19-9 level were unchanged with perillyl alcohol treatment. Survival time was longer in patients who received full perillyl alcohol treatment (288 ± 32 days) compared to those who did not (204 ± 96 days), but this result did not achieve statistical significance (P = 0.2). There was a trend toward greater apoptosis in patients receiving perillyl alcohol compared to fresh operative controls; there was also a suggestion of greater apoptosis in tumor compared to normal pancreatic tissue in the same patient. Conclusions: Incorporation of cell-specific biological endpoints is challenging but feasible and should be used in clinical studies of pancreatic cancer treatment. Our pilot study suggests that perillyl alcohol may indeed have effects on biological endpoints. This study will serve as a useful template for examining cell-specific biological endpoints in the testing of future agents that are thought to induce apoptosis in pancreatic cancer.",
keywords = "apoptosis, Bak, pancreatic cancer, perillyl alcohol",
author = "Matos, {Jesus M.} and C. Schmidt and Thomas Howard and Oscar Cummings and Wiebke, {Eric A.} and Madura, {James A.} and Patrick Loehrer and Crowell, {P. L.}",
year = "2008",
month = "6",
day = "15",
doi = "10.1016/j.jss.2008.02.005",
language = "English",
volume = "147",
pages = "194--199",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - A Pilot Study of Perillyl Alcohol in Pancreatic Cancer

AU - Matos, Jesus M.

AU - Schmidt, C.

AU - Howard, Thomas

AU - Cummings, Oscar

AU - Wiebke, Eric A.

AU - Madura, James A.

AU - Loehrer, Patrick

AU - Crowell, P. L.

PY - 2008/6/15

Y1 - 2008/6/15

N2 - Background: Chemotherapy has been largely unsuccessful in pancreatic cancer. Measurement of cell-specific biological endpoints may clarify the evaluation of a newer generation of compounds. Perillyl alcohol has shown chemotherapeutic activity in preclinical systems through enhancing apoptosis. Aims: To pilot a new trial template for testing novel agents in pancreatic cancer and to assess the biological activity of perillyl alcohol in patients with resectable pancreatic cancer. Methods: Apoptosis was quantified with ApopTag in situ, Bak staining, and light microscopy. Tumor size, serum CA 19-9 level, and survival were also measured. Results: Eight patients enrolled. Toxicity was mild and perillyl alcohol was generally well tolerated. Tumor size and CA 19-9 level were unchanged with perillyl alcohol treatment. Survival time was longer in patients who received full perillyl alcohol treatment (288 ± 32 days) compared to those who did not (204 ± 96 days), but this result did not achieve statistical significance (P = 0.2). There was a trend toward greater apoptosis in patients receiving perillyl alcohol compared to fresh operative controls; there was also a suggestion of greater apoptosis in tumor compared to normal pancreatic tissue in the same patient. Conclusions: Incorporation of cell-specific biological endpoints is challenging but feasible and should be used in clinical studies of pancreatic cancer treatment. Our pilot study suggests that perillyl alcohol may indeed have effects on biological endpoints. This study will serve as a useful template for examining cell-specific biological endpoints in the testing of future agents that are thought to induce apoptosis in pancreatic cancer.

AB - Background: Chemotherapy has been largely unsuccessful in pancreatic cancer. Measurement of cell-specific biological endpoints may clarify the evaluation of a newer generation of compounds. Perillyl alcohol has shown chemotherapeutic activity in preclinical systems through enhancing apoptosis. Aims: To pilot a new trial template for testing novel agents in pancreatic cancer and to assess the biological activity of perillyl alcohol in patients with resectable pancreatic cancer. Methods: Apoptosis was quantified with ApopTag in situ, Bak staining, and light microscopy. Tumor size, serum CA 19-9 level, and survival were also measured. Results: Eight patients enrolled. Toxicity was mild and perillyl alcohol was generally well tolerated. Tumor size and CA 19-9 level were unchanged with perillyl alcohol treatment. Survival time was longer in patients who received full perillyl alcohol treatment (288 ± 32 days) compared to those who did not (204 ± 96 days), but this result did not achieve statistical significance (P = 0.2). There was a trend toward greater apoptosis in patients receiving perillyl alcohol compared to fresh operative controls; there was also a suggestion of greater apoptosis in tumor compared to normal pancreatic tissue in the same patient. Conclusions: Incorporation of cell-specific biological endpoints is challenging but feasible and should be used in clinical studies of pancreatic cancer treatment. Our pilot study suggests that perillyl alcohol may indeed have effects on biological endpoints. This study will serve as a useful template for examining cell-specific biological endpoints in the testing of future agents that are thought to induce apoptosis in pancreatic cancer.

KW - apoptosis

KW - Bak

KW - pancreatic cancer

KW - perillyl alcohol

UR - http://www.scopus.com/inward/record.url?scp=43549111580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43549111580&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2008.02.005

DO - 10.1016/j.jss.2008.02.005

M3 - Article

C2 - 18498869

AN - SCOPUS:43549111580

VL - 147

SP - 194

EP - 199

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -